| [1] |
Li N, Xu L, Liu X, et al. Castleman disease misdiagnosed as immunoglobulin G4-related diseiase: A case report[J]. Front Immunol, 2025, 16:1532627. doi:10.3389/fimmu.2025.1532627.
|
| [2] |
Molacek J, Treska V, Skalicky T, et al. Unicentric form of Castleman'sdisease pitfalls of diagnosis and surgical treatment[J]. Front Oncol, 2023, 13:1057683. doi:10.3389/fonc.2023.1057683.
|
| [3] |
Nishimura MF, Nishimura Y, Nishikori A, et al. Historical and pathologicaloverview of Castleman disease[J]. J Clin Exp Hematop, 2022, 62(2):60-72.doi:10.3960/jslrt.21036.
pmid: 35474035
|
| [4] |
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20):2115-2124. doi:10.1182/blood-2018-07-862334.
pmid: 30181172
|
| [5] |
张林, 罗继文. Castleman病研究进展[J]. 海南医学, 2024, 35(22):3327-3330.doi:10.3969/j.issn.1003-6350.2024.22.028.
|
| [6] |
Shahidi H, Myers JL, Kvale PA. Castleman's disease[J]. Mayo Clin Proc, 1995, 70(10):969-977.doi: 10.4065/70.10.969.
pmid: 7564550
|
| [7] |
Patel JP, Patel DP, Amin TH, et al. Castleman disease: A rare lymphoproliferative disorder with diverse clinical presentation, diagnosis, and treatment approach[J]. Cureus, 2024, 16(9):e69149.doi:10.7759/cureus.69149.
|
| [8] |
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 司妥昔单抗中国专家推荐临床应用指导原则(2024年版)[J]. 白血病·淋巴瘤, 2024, 33(8):449-455.doi:10.3760/cma.j.cn115356-20240524-00072.
|
| [9] |
Zhao S, Wan Y, Huang Z, et al. Imaging and clinical features of Castleman Disease[J]. Cancer Imaging, 2019, 19(1):53.doi: 10.1186/s40644-019-0238-0.
pmid: 31345268
|
| [10] |
Wang G, Xu Q, Liu Y, et al. 18F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease[J]. Cancer Imaging, 2025, 25(1):12.doi:10.1186/s40644-025-00833-9.
pmid: 39940060
|
| [11] |
Lang D, Zwerina J, Pieringer H. IgG4-related disease: Current challenges and future prospects[J]. Ther Clin Risk Manag, 2016:189-199.doi:10.2147/TCRM.S99985.
|
| [12] |
Sikora M, Dᶏbrowska-Leonik N, Buda P, et al. Castleman disease-still more questions than answers: A case report and review of the literature[J]. J Clin Med, 2025, 14(8):27-99. doi: 10.3390/jcm14082799.
|
| [13] |
Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: A systematic literature review[J]. Lancet Haematol, 2016, 3(4): e163-e175.doi: 10.1016/S2352-3026(16)00006-5.
|
| [14] |
van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease[J]. Blood Adv, 2020, 4(23):6039-6050.doi:10.1182/bloodadvances.2020003334.
pmid: 33284946
|
| [15] |
Pria AD, Pinato D, Roe J, et al. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients[J]. Blood, 2017, 129(15) : 2143-2147.doi: 10.1182/blood-2016-10-747477.
pmid: 28143881
|
| [16] |
Li H, Wang L, Li X, et al. Serum IgE levels are associated with the prognosis of minimal change disease[J]. Front Immunol, 2022, 13:840-857.doi:10.3389/fimmu.2022.840857.
|
| [17] |
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease[J]. Blood, 2020, 135(16):1353-1364.doi: 10.1182/blood.2019000931.
pmid: 32106302
|
| [18] |
Xu Y, Shao S, Kang H, et al. A unicentric center, multicenter, and mixed-type Castleman disease: Three case reports and a review of the literature[J]. Medicine (Baltimore), 2024, 103(15):e37722.doi:10.1097/MD.0000000000037722.
|